Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 15:363:153-7.
doi: 10.1016/j.jns.2016.02.042. Epub 2016 Feb 20.

Gut microbiota composition and relapse risk in pediatric MS: A pilot study

Collaborators, Affiliations

Gut microbiota composition and relapse risk in pediatric MS: A pilot study

Helen Tremlett et al. J Neurol Sci. .

Abstract

We explored the association between baseline gut microbiota (16S rRNA biomarker sequencing of stool samples) in 17 relapsing-remitting pediatric MS cases and risk of relapse over a mean 19.8 months follow-up. From the Kaplan-Meier curve, 25% relapsed within an estimated 166 days from baseline. A shorter time to relapse was associated with Fusobacteria depletion (p=0.001 log-rank test), expansion of the Firmicutes (p=0.003), and presence of the Archaea Euryarchaeota (p=0.037). After covariate adjustments for age and immunomodulatory drug exposure, only absence (vs. presence) of Fusobacteria was associated with relapse risk (hazard ratio=3.2 (95% CI: 1.2-9.0), p=0.024). Further investigation is warranted. Findings could offer new targets to alter the MS disease course.

Keywords: 16S rRNA; Cox regression; Gut microbiota; Kaplan-Meier; Pediatric multiple sclerosis; Relapse risk; Survival analyses.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Association between gut microbiota (phylum-level) and relapse for: Fusobacteria [panel A, top], Firmicutes [panel B: middle] and Euryarchaeota [panel C, bottom]
Panel A: Fusobacteria: Kaplan-Meier curves (left), absent (dashed line) vs. present (solid line). p=0.001, log-rank test. Panel B: Firmicutes: Kaplan-Meier curves (left), lower relative abundance (dashed line) vs. higher (solid line), p=0.003. log-rank test. Panel C Euryarchaeota: Kaplan-Meier curves (left), absent (dashed) vs present (solid linegreen), p=0.037, log-rank test. Key: IMD=immunomodulatory drug. Hazard ratios indicate risk of relapse from baseline and are derived from Cox regression hazards models. Age at baseline (stool collection) and IMD exposure at baseline (exposed vs. naïve) were used to adjust models as shown. Bold indicates p<0.05. Binomial categories for each phylum were created based on the data distribution as either absent versus present or high versus low (≤ vs. > median relative abundance). Of the Fusobacterium phyla identified, the genera were either Fusobacterium or Leptotrichia (genus was the lowest taxonomic level available).
Figure 1
Figure 1. Association between gut microbiota (phylum-level) and relapse for: Fusobacteria [panel A, top], Firmicutes [panel B: middle] and Euryarchaeota [panel C, bottom]
Panel A: Fusobacteria: Kaplan-Meier curves (left), absent (dashed line) vs. present (solid line). p=0.001, log-rank test. Panel B: Firmicutes: Kaplan-Meier curves (left), lower relative abundance (dashed line) vs. higher (solid line), p=0.003. log-rank test. Panel C Euryarchaeota: Kaplan-Meier curves (left), absent (dashed) vs present (solid linegreen), p=0.037, log-rank test. Key: IMD=immunomodulatory drug. Hazard ratios indicate risk of relapse from baseline and are derived from Cox regression hazards models. Age at baseline (stool collection) and IMD exposure at baseline (exposed vs. naïve) were used to adjust models as shown. Bold indicates p<0.05. Binomial categories for each phylum were created based on the data distribution as either absent versus present or high versus low (≤ vs. > median relative abundance). Of the Fusobacterium phyla identified, the genera were either Fusobacterium or Leptotrichia (genus was the lowest taxonomic level available).
Figure 1
Figure 1. Association between gut microbiota (phylum-level) and relapse for: Fusobacteria [panel A, top], Firmicutes [panel B: middle] and Euryarchaeota [panel C, bottom]
Panel A: Fusobacteria: Kaplan-Meier curves (left), absent (dashed line) vs. present (solid line). p=0.001, log-rank test. Panel B: Firmicutes: Kaplan-Meier curves (left), lower relative abundance (dashed line) vs. higher (solid line), p=0.003. log-rank test. Panel C Euryarchaeota: Kaplan-Meier curves (left), absent (dashed) vs present (solid linegreen), p=0.037, log-rank test. Key: IMD=immunomodulatory drug. Hazard ratios indicate risk of relapse from baseline and are derived from Cox regression hazards models. Age at baseline (stool collection) and IMD exposure at baseline (exposed vs. naïve) were used to adjust models as shown. Bold indicates p<0.05. Binomial categories for each phylum were created based on the data distribution as either absent versus present or high versus low (≤ vs. > median relative abundance). Of the Fusobacterium phyla identified, the genera were either Fusobacterium or Leptotrichia (genus was the lowest taxonomic level available).

References

    1. Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature. 2011;479:538–41. - PubMed
    1. Lee YK, Menezes JS, Umesaki Y, Sarkis K, Mazmaniana SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4615–4622. - PMC - PubMed
    1. Mielcarz DW, Kasper LH. The Gut Microbiome in Multiple Sclerosis. Curr Treat Options Neurol. 2015 Apr;17(4):344. doi: 10.1007/s11940-015-0344-7. - PubMed
    1. Ochoa-Reparaz J, Mielcarz DW, Ditrio LE, Burroughs AR, Begum-Haque S, Dasgupta S, et al. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression. J Immunol. 2010;185:4101–4108. - PubMed
    1. Tremlett H, Fadrosh DW, Faruqi AA, et al. Gut microbiota in early pediatric multiple sclerosis: a case-control study. 2016 Under review. - PMC - PubMed

Publication types

Substances